Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-NH-PEG1-NH2 TFA is an E3 ligase ligand-linker conjugate that targets Cereblon (CRBN). This compound serves as a critical ligand to recruit the CRBN protein, facilitating the development of proteolysis-targeting chimeras (PROTACs). It plays a significant role in studies focused on targeted protein degradation and E3 ligase modulation in biochemical and pharmacological research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that utilizes the cereblon ligand derived from Thalidomide. This compound serves as a vital component in the development of PROTAC (proteolysis-targeting chimeras) technology, enabling targeted protein degradation. Thalidomide-O-C7-acid is instrumental for researchers focusing on protein regulation and therapeutic applications in various disease models. -
E3 Ligase Ligand-Linker Conjugate
Deoxy-thalidomide-Pip-C-PIP-boc is a conjugate that functions as an E3 ligase ligand-linker complex, featuring Thalidomide as a critical component. This compound acts as a Cereblon ligand, facilitating the recruitment of the CRBN protein, which is essential for targeted protein degradation. It serves as a vital intermediate in the synthesis of complete PROTAC (Proteolysis Targeting Chimeras) molecules, making it valuable for research in targeted therapeutic strategies and protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PIP-(R)C-pyrrolidine-boc is a conjugate that acts as an E3 ligase ligand-linker complex, incorporating Thalidomide as the enabling component. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein and serving as a crucial intermediate in the synthesis of PROTAC molecules. Its role in targeted protein degradation makes it a valuable tool for addressing complex biological questions in chemical biology and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C5-NH2 is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand, designed for applications in PROTAC (Proteolysis Targeting Chimeras) technology. This compound facilitates targeted protein degradation, enabling researchers to investigate proteostasis and elucidate cellular mechanisms. Its use in drug discovery can enhance the development of novel therapeutics by modulating protein levels and activity in complex biological systems. -
E3 Ligase Ligand-Linker Conjugate
Ethanolamine-Thalidomide-4-OH is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via the proteolysis targeting chimera (PROTAC) approach. This compound combines a cereblon (CRBN) ligand with a linker, enabling the synthesis of various PROTACs, such as PROTAC BTK Degrader-13. It serves as a crucial tool for researchers investigating selective protein degradation mechanisms and developing novel therapeutic strategies. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 214 is an innovative E3 ligase ligand-linker conjugate featuring a Von Hippel-Lindau (VHL) ligand. This compound effectively binds to target proteins, facilitating the formation of PROTAC (Proteolysis Targeting Chimeras) molecules, such as the PROTAC LSD1 Degrader 1. Its application in targeted protein degradation research supports the development of novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-COOH is an E3 ligase ligand-linker conjugate designed for the construction of PROTACs. It incorporates the VH032 VHL-based ligand, which is a selective and potent inhibitor of the VHL/HIF-1α interaction with a Kd of 185 nM. This compound is valuable for investigating models of anemia and ischemic diseases, providing a tool for targeted protein degradation research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-(1-(3-azetidinylmethyl)piperazine) is an E3 ligase ligand-linker conjugate designed for targeted protein degradation via the PROTAC (proteolysis-targeting chimera) platform. This compound features a CRBN-based ligand that facilitates the recruitment of E3 ubiquitin ligase, enabling selective degradation of target proteins. It is a valuable tool for researchers investigating protein regulation, cellular pathways, and therapeutic strategies in drug discovery and development. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-C-piperazine hydrochloride is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand and a versatile linker. This compound serves as a critical component in the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation. It is suitable for research applications focused on protein regulation and therapeutic development in oncology and other fields. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-C-piperidin is an E3 ligase ligand-linker conjugate that includes a CRBN-based ligand. This compound is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation. It serves as a versatile tool in drug discovery and basic research aimed at modulating protein levels within biological systems. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C6-Br is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation. This compound plays a crucial role in the synthesis of PROTAC EGFR degrader 9, enabling selective degradation of the epidermal growth factor receptor (EGFR). Its innovative design allows for precise modulation of protein levels, making it valuable in studies focused on therapeutic approaches for cancer and other diseases linked to EGFR dysregulation. -
E3 Ligase Ligand-linker Conjugate
Lenalidomide-acetylene-C3-MsO is an E3 ligase ligand-linker conjugate designed for the synthesis of specific drug conjugates, such as SIAIS039. This compound enables targeted protein degradation through the activation of the ubiquitin-proteasome system. Its utility in research encompasses the investigation of protein interactions and the development of novel therapeutic strategies in cellular models. -
E3 Ligase Ligand-Linker Conjugate
Dihydrouracil-Ph-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a CRBN-based ligand that facilitates selective recruitment of E3 ligases, enabling the synthesis of PROTACs (proteolysis-targeting chimeras). It serves as a valuable tool for researchers exploring degradation-based therapies and the modulation of cellular protein levels. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-piperazine-azetidine is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand attached to a versatile linker. This compound is designed to facilitate the synthesis of PROTACs (proteolysis targeting chimeras), enabling targeted degradation of specific proteins within cellular systems. Key applications include the investigation of protein function and the development of novel therapeutic strategies for diseases associated with dysregulated protein levels. -
E3 Ligase Ligand-Linker Conjugate
3-(1-Oxo-5-(3,9-diazaspiro[5.5]undecan-3-yl)isoindolin-2-yl)piperidine-2,6-dione is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates a CRBN-based ligand, enabling the synthesis of PROTAC (Proteolysis Targeting Chimeras) for selective protein modulation. It serves as a critical tool in chemical biology for studying protein function and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
(S)-Phthalimidinoglutarimide-6-piperazine is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound serves as a key component in the synthesis of PROTAC SMARCA2 degrader-35, facilitating the selective degradation of the SMARCA2 protein. Its role in research underscores its potential for advancing studies in targeted therapeutics and proteostasis modulation. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-azetidine hydrochloride is an E3 ligase ligand-linker conjugate that utilizes a cereblon (CRBN)-based ligand in conjunction with a linker moiety. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras), which can selectively target and degrade specific proteins within cellular systems. Its application in drug discovery and development enhances the understanding of protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG2-NHS ester is an E3 ligase ligand-linker conjugate that incorporates thalidomide-derived cereblon ligands with a PEG linker, facilitating targeted protein degradation via PROTAC technology. This compound is designed for use in research applications involving ubiquitin-proteasome system studies, enabling the modulation of protein levels in a cellular context. Its unique properties make it suitable for exploring therapeutics that can selectively eliminate disease-associated proteins. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-(R)-pyrrolidine-3-carbaldehyde is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted degradation of specific proteins within cellular systems. Its unique structure enables efficient recruitment of E3 ligases, making it essential for studies in targeted protein degradation and drug development. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-Pip hydrochloride is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN) ligand and a linker moiety. This compound is designed for the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation. Its effective engagement with E3 ligases facilitates the selective modulation of protein levels, making it valuable for research in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
DGY-02-126-O-C-COOH is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand and a suitable linker. This compound facilitates the synthesis of PROTAC (Proteolysis Targeting Chimera) molecules, which are instrumental in targeted protein degradation research. Its unique structure supports the development of innovative therapeutic strategies by modulating protein interactions within cellular systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-tert-butyl formate is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand, facilitating targeted protein degradation through the PROTAC (Proteolysis Targeting Chimera) approach. This compound acts by engaging E3 ligases, promoting ubiquitination and subsequent proteasomal degradation of target proteins. It is valuable for research applications involving protein regulation, cellular signaling, and the development of novel therapeutic strategies in various disease contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-C3-NH2 hydrochloride serves as an E3 ligase ligand-linker conjugate, featuring a cereblon (CRBN)-based ligand linked to a suitable chemical moiety. This compound is pivotal for the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating selective protein degradation pathways. Its application in chemical biology research extends to targeted protein degradation and the investigation of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-Piperazine-piperidine hydrochloride is a ligand-linker conjugate targeting E3 ligases, specifically designed for the synthesis of PROTAC (proteolysis-targeting chimera) compounds. This molecule features a CRBN-based ligand, facilitating targeted protein degradation for elucidating protein function and potential therapeutic applications. Its utility in drug discovery and development supports research in protein homeostasis and cellular regulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-Pip dihydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a CRBN-based ligand combined with a linker, facilitating the synthesis of PROTACs (Proteolysis Targeting Chimeras). It is suitable for research involving the modulation of protein levels in various biological pathways, providing valuable insights into cellular processes and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-Piperazine-piperidine dihydrochloride is a conjugate designed to target E3 ligases, specifically featuring a CRBN-based ligand and linker. This compound is instrumental in the synthesis of PROTACs, facilitating the targeted degradation of proteins in various research applications. It serves as a valuable tool for studying protein homeostasis and elucidating cellular mechanisms related to protein turnover. -
E3 Ligase Ligand-Linker Conjugate
Amino-PEG4-(S,R,S)-AHPC-Me is a ligand-linker conjugate designed for E3 ligase targeting. This compound facilitates the development of PROTACs, specifically enabling the synthesis of NR-V04. It is utilized in research applications focused on targeted protein degradation and the modulation of protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
(S)-Thalidomide-azetidine-O-Pip is an E3 ligase ligand-linker conjugate designed for targeted protein degradation via the knockdown of specific proteins. This compound features a CRBN-based ligand that enables the selective recruitment of E3 ligases, facilitating the formation of PROTACs (PROteolysis TArgeting Chimeras). It is valuable in studies focused on therapeutic strategies, cancer research, and functional proteomics. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C10-Boc is a conjugate designed as an E3 ubiquitinase ligand-linker, facilitating the recruitment of the Cereblon ubiquitinase. This compound enables the synthesis of PROTAC molecules that induce targeted protein degradation, through its versatile PTOTAC linker. It has applications in developing therapeutics by coupling with specific ligands, such as EP300/CBP ligand 2, to create PROTACs that promote proteolytic activity against designated targets. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-COCH-PEG2-azido is an E3 ligase ligand-linker conjugate designed to target cereblon, facilitating the development of targeted protein degradation strategies. This compound plays a crucial role in synthesizing PROTAC AKR1C3 degrader-1, aiding researchers in studying protein turnover and degradation pathways. It is particularly useful in the investigation of cellular responses to E3 ligase modulation and the development of novel biotherapeutic approaches. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-Triazole-C4-amino is an E3 ligase ligand-linker conjugate that facilitates the formation of proteolysis-targeting chimeras (PROTACs). This compound is essential for researchers investigating targeted protein degradation mechanisms, providing a robust approach to modulate specific protein levels within cells. It plays a significant role in drug development and environmental toxicity research applications by enabling the selective degradation of disease-related proteins. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 109 is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC SOS1 degrader. This compound facilitates targeted protein degradation, enabling researchers to investigate the therapeutic potential of protein modulation in cellular systems. Its utility in developing targeted degradation strategies makes it an essential tool for drug discovery and development research. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-pent-4-yn-1-ol is an E3 ligase ligand-linker conjugate designed to facilitate the synthesis of PROTACs (proteolysis-targeting chimeras). This compound utilizes a CRBN-based ligand in conjunction with a pent-4-yn-1-ol linker, enabling targeted degradation of proteins through the ubiquitin-proteasome pathway. It serves as a valuable tool for studying protein regulation and therapeutic interventions in diseases related to protein misfolding and degradation. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-Me-8-bromooctanoic acid is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC compounds. This reagent facilitates the targeted degradation of proteins, specifically functioning in the development of CYP1B1 degrader-2. It is a valuable tool for researchers investigating targeted protein degradation and related therapeutic applications in drug discovery. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-((3R)-3-pyrrolidinemethanol) is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand and attached linker. This compound is essential for the design and synthesis of PROTACs (proteolysis targeting chimeras), which facilitate the degradation of specific proteins within cellular systems. Its ability to selectively target E3 ligases makes it a valuable tool in chemical biology research and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 108 is an E3 ligase ligand-linker conjugate designed for the synthesis of targeted protein degradation compounds. This reagent facilitates the development of PROTACs, specifically enabling the degradation of the SOS1 protein. It serves as a crucial tool in research applications focused on targeted protein modulation and therapeutic intervention in cellular processes related to disease states. -
E3 Ligase Ligand-Linker Conjugate
tert-Butyl (S)-5-amino-4-(4-hydroxy-1-oxoisoindolin-2-yl)-5-oxopentanoate serves as an E3 ligase ligand-linker conjugate specifically designed for the development of PROTACs (proteolysis-targeting chimeras). This compound features a CRBN-based ligand essential for targeted protein degradation mechanisms. Its application in research facilitates the selective modulation of protein levels, contributing to studies in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide 5'-piperazine-C1-piperidine is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand coupled with a linker moiety. This compound is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted protein degradation. Its primary application lies in the study and modulation of protein levels in various biological contexts, making it an essential tool for cancer research and drug discovery. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-CO-C3-COOH is an E3 ligase ligand-linker conjugate featuring a VHL ligand combined with a linker structure derived from (S,R,S)-AHPC. This versatile compound facilitates the design and synthesis of PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation. Its unique structure supports research applications in targeted therapy and cellular protein regulation studies. -
E3 ligase ligand-Linker Conjugate
VH285-PEG4-C4-Cl is an E3 ligase ligand-linker conjugate that employs a halogenated connector within its 16-atom length linker. This compound combines the VH285-based VHL ligand with an alkyl/ether-based linker, demonstrating high efficacy as a degrader of GFP-HaloTag7 with a DC50 of 19 nM. VH285-PEG4-C4-Cl achieves approximately 90% degradation of GFP-HaloTag7 at a concentration of 625 nM and exhibits an IC50 value of 0.54 μM for binding to VHL. This compound is ideal for researchers investigating targeted protein degradation and E3 ligase interactions. -
neoDegrader-Linker Conjugate
MC-VC-PABC-amide-PEG1-CH2-CC-885 is a neoDegrader-Linker conjugate designed for targeted protein degradation through the GSPT1 degrader CC-885. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling conjugation with antibodies such as DAR3.7, which specifically targets CD56. It is primarily utilized in research applications focused on cancer therapeutics and targeted degradation strategies. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG3-N3 is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound features the (S,R,S)-AHPC-based VHL ligand and a three-unit PEG linker, enabling efficient conjugation for targeted protein degradation. The presence of an azide group allows it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules or those featuring DBCO or BCN groups. Its applications include the development of targeted therapeutics and exploring the dynamics of protein regulation in various biological systems. -
Molecular Glue
Pomalidomide 5'-pip-acid is a molecular glue that functions as a dual-target PROTAC degrader, specifically targeting CBP/p300 and BRD4. It exhibits significant antiproliferative activity against cancer cells, with an IC50 value of 2.73 nM. This compound is particularly relevant for research in prostate and colorectal cancer, offering a valuable tool for investigating targeted degradation pathways in oncogenesis. -
E3 Ligase Lgand-Linker Conjugate
(S,R,S)-AHPC-Me-amide-C-O-PEG2-COOH is an E3 ligase ligand-linker conjugate designed for use in the synthesis of proteolysis targeting chimeras (PROTACs). This compound facilitates targeted degradation of specific proteins by harnessing the ubiquitin-proteasome system, enabling researchers to investigate protein function and modulation within cellular pathways. Its unique structure allows for efficient conjugation and enhances the bioavailability of PROTACs in various biological studies. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG4-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines the pomalidomide-derived cereblon ligand with a four-unit polyethylene glycol (PEG) linker. This compound is designed for use in the development of PROTACs (proteolysis targeting chimeras), facilitating targeted protein degradation. Its unique structure enables efficient binding to specific E3 ligases, making it a valuable tool for research in targeted therapy and protein management. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-C6-NH2 is an E3 ligase ligand-linker conjugate designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound incorporates the VHL ligand, facilitating targeted protein degradation through the recruitment of E3 ligases. Its application in drug development provides a novel approach for modulating protein levels within cellular systems, making it valuable for researchers investigating targeted therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-PEG1-C2-N3 is an E3 ligase ligand-linker conjugate that combines a Pomalidomide-based cereblon ligand with a one-unit PEG linker, facilitating the development of PROTACs. This compound is particularly effective in creating selective CDK6 degrader molecules, such as CP-10, which induces CDK6 degradation with a DC50 of 2.1 nM. Additionally, Pomalidomide-PEG1-C2-N3 features an azide functionality that enables it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions, making it a versatile tool for click chemistry applications in chemical biology. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that utilizes the (S,R,S)-AHPC derived VHL ligand in conjunction with a five-unit PEG linker. This compound is primarily designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. Its key biological activity includes effective binding to E3 ligases, enhancing the recruitment of specific substrates for ubiquitination and subsequent proteasomal degradation. This reagent is valuable for various research applications in the fields of targeted protein modulation and cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugates Chemical
(S,R,S)-AHPC-CO-C9-acid functions as a ligand-linker conjugate targeting E3 ligases, facilitating the formation of proteolysis-targeting chimeras (PROTACs). This compound enables the selective degradation of target proteins by linking a ligand to an E3 ligase, allowing for enhanced manipulation of cellular pathways. Its application is critical in chemical biology and drug discovery, particularly for studying protein interactions and degrading disease-associated proteins.
